Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuBase Therapeutics Inc

UiPath

Portage Biotech Inc

Richardson Electronics

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

New Strong Buy Stocks for January 20th

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.33% and 18.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates

- mWTX-330 is designed as a systemically delivered, conditionally activated IL-12 therapy and is a member of a novel class of INDUKINE™ therapeutics -

Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting

WATERTOWN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today provided a business update and reported financial results for the third quarter ended September 30, 2022.

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced upcoming oncology research and investor community events in which Werewolf scientists and management will participate.

Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference, taking place in New York, NY from September 12-14, 2022.

Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

- First clinical candidate of a new class of systemically delivered conditionally activated INDUKINE™ therapeutics developed by Werewolf

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1/1b Clinical Trial of WTX-124 for the Treatment of Patients with Selected Solid Tumors

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors -

Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

WATERTOWN, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference being held from August 9-10, 2022.

Werewolf Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:00AM ET on June 9 during the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.

Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

- Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613; received $15.0M upfront payment and eligibility for up to $1.26B in downstream milestones as well as royalties on potential future sales -

Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

Axsome Therapeutics

Infinity Pharma

Jazz Pharmaceuticals

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.

JAZZ Inks Deal With Werewolf to Add Oncology Candidate

WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner

Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NASDAQ: HOWL) WTX-613. WTX-613 is a differentiated, conditionally-activated interferon-alpha (IFNα) INDUKINE molecule.

Werewolf Therapeutics Shares Jump On Cancer Product Pact With Jazz Pharma

Shares of Werewolf Therapeutics Inc. jumped 10.8% in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to $1.2 billion. Jazz now has exclusive development and commercialization rights to Werewolf's preclinical immuno-oncology candidate and plans to submit the molecule for Food and Drug Administration approval in 2023.

Jazz, Werewolf sign licensing deal worth up to $1.2 billion

Werewolf to receive $15 million upfront payment, with potential for up to $1.26 billion in development, regulatory and sales milestone payments in addition to royalties on future net sales WTX-613 expands Jazz's robust oncology pipeline and represents first immuno-oncology program in company's R&D portfolio DUBLIN and CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Werewolf Therapeutics, Inc. (Nasdaq: HOWL) today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule.

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule

-Closed upsized IPO in May 2021 raising $120 million in gross proceeds-

Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 (IL-2) INDUKINE™ molecule. The article, entitled “Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression,” includes preclinical data that demonstrate the efficacy of the design of WTX-124 in delivering IL-2 selectively to the tumor microenvironment where it stimulates a potent anti-tumor immune response.

Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of two abstracts summarizing upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will take place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting

CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.

Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022.

Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Werewolf Therapeutics Added to the Nasdaq Biotechnology Index

Data demonstrates the strength of Werewolf's innovative therapeutic approach across multiple conditionally activated pipeline programs Data demonstrates the strength of Werewolf's innovative therapeutic approach across multiple conditionally activated pipeline programs

Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting

-Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program-

News for Werewolf Therapeutics Stock (HOWL)